DKSH has formed a strategic partnership with Alpro Pharmacy Sdn. Bhd., Malaysia’s largest prescription pharmacy chain to enhance medication access across Malaysia.
Petaling Jaya, Malaysia, August 30, 2024 – DKSH Business Unit Healthcare, a leading strategic partner for companies seeking to grow their healthcare business in Asia and beyond, has successfully entered into a strategic partnership with Alpro Pharmacy, the largest prescription pharmacy chain in Malaysia. This collaboration aims to increase access, through addressing affordability challenges, to essential medication for all patients nationwide. Moreover, this partnership enhances the well-being of Thalassemia patients, strengthens Malaysia’s healthcare landscape, and aligns seamlessly with Alpro Pharmacy’s vision and initiative of ONCOHelp – a one-stop center for cancer patients across Malaysia.
Under the agreement, DKSH’s Patient Access Program (PAP) will provide financial support to patients from selected Alpro Pharmacies.
DKSH’s Patient Solutions support network is expanding across eight markets in APAC; touching the lives of many patients, healthcare professionals, and healthcare brands through various patient support programs that address challenges patients face in their treatment journey from accessibility to education and convenience. The team actively listens to the needs of its stakeholders and strives to continuously address them, tackling challenges in healthcare delivery and consumption across APAC. This partnership with Alpro Pharmacy will increase accessibility of drugs for patients and lead to adherence and hence improved treatment outcomes.
Joelle Wong Pei Sen, Chief Pharmaceutical Officer, ONCOHelp, Alpro Pharmacy, commented: “DKSH’s regional experience in managing Patient Access Programs across the Asia Pacific region (APAC) is essential for benefiting our patients. Together, we are confident that we can enhance healthcare accessibility and improve the quality of life for many individuals across Malaysia.”
Sandeep Tewari, Head Country Management and Vice President, Healthcare, DKSH Malaysia, added: “DKSH’s mission is to enrich people’s quality of life by providing better healthcare solutions. Our goal is to address the challenges patients encounter throughout their treatment journey. The PAP aims to make high-cost drugs more accessible. Through this collaboration, patients can conveniently obtain medications from designated Alpro Pharmacy outlets near their treating hospitals ensuring healthcare for all. This partnership also supports the well-being of Thalassemia patients and positively impacts the overall Malaysia’s healthcare landscape.”
About Alpro Pharmacy
Alpro Pharmacy is Malaysia’s largest prescription pharmacy chain, with over 300 locations across the country. Their extensive healthcare ecosystem includes dedicated professionals such as pharmacists, medical doctors, nutritionists, dietitians, and physiotherapists. They offer a wide range of innovative services, including the Medi Series, Home Physio, Silvercare, Sug0365, and Minute Consult. In addition, Alpro Pharmacy is proud to support ONCOHelp, a one-stop center for cancer patients. In June 2023, they partnered with the National Cancer Society of Malaysia (NCSM) to improve the lives of cancer patients and survivors, emphasizing on facilitating access to affordable genuine cancer medications. The key objectives of ONCOHelp under Alpro Pharmacy includes easy access to medications, affordable pricing and financial aid, and shorter lead times for medication supply. www.alpropharmacy.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales ser-vices. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 bil-lion in 2023. www.dksh.com/hec